Orphan Status news from FierceBiotech
News
Osiris sells stem cell business to NuVasive
Medical device maker NuVasive is buying Osteocel, Osiris' biologics business, for $35 million up front and an additional $50 million in milestone payments. The Osteocel business includes an adult Read more...
Pharming shares sink after Rhucin gets thumbs down
There's new trouble for Pharming's Rhucin, an experimental treatment for hereditary angioedema. Pharming shares plunged after the company announced that the EMEA's Committee for Medicinal Products Read more...
ChemGenex restructures, focuses on cancer drugs
ChemGenex Pharmaceuticals, which recently reported positive data on the experimental leukemia therapy Ceflatonin, says it is restructuring the company so it can focus on its cancer therapies. The Read more...
Pharming raises $99M
Netherlands-based Pharming has raised $99 million (€70 million) through the issue of convertible bonds. The issue was managed by UBS Investment Bank. The company is also finalizing discussions for Read more...
Aspreva, Roche put CellCept on ice
Shares of Aspreva Pharmaceuticals slipped a bit this morning after the company and Roche announced that they would not be pushing ahead with a regulatory filing for CellCept, a new therapy for lupus Read more...
Pharming says it's closing in on Rhucin approval
Pharming says that the positive interim results it has received from a study of Rhucin is blazing the way to EMEA approval. The Amsterdam-based developer says it expects EMEA approval in the fourth Read more...
Chelsea wins European orphan status
European drug regulators granted orphan drug status to Chelsea Therapeutics' remedy for hypotension, Droxidopa, and recommended the same for Progen's experimental liver drug, known as PI-88. Designed Read more...
Regulators focusing on transgenic animals
Genetically engineered animals are producing a range of therapies for human use, and The New York Times catches up on the action at companies like Read more...
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends